Advertisement Salong Debbarma, Author at Pharmaceutical Business review - Page 2 of 15
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

All articles by Salong Debbarma

NewcelX and Eledon partner for NCEL-101 programme

The collaboration will integrate NewcelX’s NCEL-101 with Eledon’s investigational anti-cluster of differentiation 40 ligand (anti-CD40L) monoclonal antibody, tegoprubart (AT-1501), to support durable, immune-protected islet replacement and develop a